Advertisement
CANF vs CMMB
Which Stock Would AI Choose? Can-Fite BioPharma Ltd. (CANF) vs. Chemomab Therapeutics Ltd. (CMMB) Stock Comparison
Key Takeaways
- Both CANF and CMMB are clinical-stage Israeli biotechnology companies with limited revenue, ongoing net losses, and share prices that have trended lower over the past year.
- CANF is advancing multiple late-stage small-molecule candidates, while CMMB is repositioning around an antibody platform through a pending merger with Scipher Medicine.
- CMMB carries a defined near-term corporate catalyst, whereas CANF has faced sustained dilution pressure from discounted warrant exercises.
- Tickeron AI Verdict: CMMB — its clearer near-term catalyst and relatively steadier sentiment profile give it a modest edge in this comparison.
- For more detail, explore CANF Major News and CANF Today's Price Move, plus CMMB Major News and CMMB Today's Price Move.
- To see how automated strategies are positioning across the market, visit Trending AI Robots.
Introduction
Investors scanning the small-cap biotech space often weigh companies with promising pipelines against their funding, dilution, and execution risks. Can-Fite BioPharma Ltd. (CANF) and Chemomab Therapeutics Ltd. (CMMB) sit at the intersection of late-stage clinical science and constrained balance sheets, making this stock comparison instructive for traders who follow catalyst-driven moves and for longer-horizon investors evaluating relative performance and market positioning. Both names are micro-cap, development-stage drugmakers, yet they are pursuing materially different strategies — one pushing multiple internal programs toward registration, the other consolidating into a precision-medicine platform. Understanding those differences is central to assessing which stock currently offers the more coherent near-term setup.
CANF Overview and Recent Performance
Can-Fite BioPharma Ltd. (CANF) is a clinical-stage biopharmaceutical company developing orally bioavailable, small-molecule drugs for cancer, liver disease, and inflammatory conditions. Its pipeline is anchored by Namodenoson and Piclidenoson, with Namodenoson in a pivotal Phase 3 liver-cancer study and Piclidenoson in a Phase 3 psoriasis program. Recent weeks have featured encouraging scientific updates, including final positive Phase 2a pancreatic-cancer data for Namodenoson presented at the ESMO 2026 (European Society for Medical Oncology) meeting, plus new patent allowances across several jurisdictions.
Despite this clinical momentum, CANF shares have trended sharply lower in recent market activity, with the stock trading near the lower end of its 52-week range and down roughly 80% over the trailing year. A key headwind has been financing-related dilution: the company has repeatedly exercised repriced warrants at a discount to raise capital, which has weighed on sentiment and technical positioning. The result is a stock with a data-rich pipeline but a persistently heavy supply overhang that has kept momentum negative.
CMMB Overview and Recent Performance
Chemomab Therapeutics Ltd. (CMMB) is a clinical-stage biotechnology company developing nebokitug, a monoclonal antibody targeting CCL24, for fibrotic and inflammatory diseases such as primary sclerosing cholangitis (a progressive liver disease) and systemic sclerosis. The defining recent development is a planned merger with precision-medicine company Scipher Medicine, announced to advance nebokitug in an artificial-intelligence-guided Phase 2 trial in rheumatoid arthritis.
In recent weeks, CMMB has moved through the formal steps of that transaction: the SEC (U.S. Securities and Exchange Commission) declared its Form S-4 registration effective, and a special shareholder meeting to vote on the merger is scheduled for early December 2026. Upon completion, Chemomab is expected to fold into a U.S.-based parent that will rebrand and list on Nasdaq under a new ticker, with roughly $30 million in new funding supporting the combined company. Shares have traded in a relatively contained range near the lower half of their 52-week band, with the merger timeline acting as the primary sentiment driver.
Trending AI Robots
Tickeron maintains a library of hundreds of AI Trading Bots that collectively monitor thousands of different tickers, each running distinct strategies, timeframes, and risk parameters. Because market conditions change constantly, not every bot is suited to the current environment — which is why Tickeron curates a dedicated Trending AI Robots section featuring the bots best matched to today's market. These automated systems vary widely in trading style, from momentum and swing approaches to longer-horizon positioning, and each carries its own performance record, win-rate statistics, and set of traded tickers. Exploring Trending AI Robots offers a data-driven way to see how quantitative strategies are interpreting relative strength and risk across names like these two biotechs.
Head-to-Head Comparison
Although both companies are small-cap Israeli biotechs, their risk profiles differ in important ways. CANF owns a broader internal pipeline with two Phase 3 programs, which diversifies its scientific optionality but also spreads limited capital across several costly trials. Its reliance on discounted warrant exercises has created repeated dilution, a factor visible in its steep price decline and weak technical structure.
CMMB, by contrast, has concentrated its exposure into a single antibody program and is effectively re-underwriting that bet through a merger that brings new capital and an AI-driven precision-medicine platform. This narrows its pipeline focus but provides a more clearly defined, near-dated catalyst. On the other hand, merger execution carries its own risks, including shareholder approval uncertainty and integration complexity. In terms of sector exposure, both are pure-play biotechnology, but CANF leans toward oncology and inflammation while CMMB leans toward fibrotic and autoimmune disease. Market sentiment has been negative for both, though CMMB has held a steadier range as its merger timeline advanced.
Tickeron AI Verdict
Weighing trend consistency, stability, catalysts, and relative positioning, Tickeron's AI framework would currently lean toward CMMB as the more favorable of the two. Its defined near-term catalyst — a merger with committed new funding and a planned Nasdaq re-listing — provides a clearer event-driven anchor than the open-ended, dilution-heavy financing path facing CANF. That said, both stocks remain speculative, development-stage names trading below key moving averages, and neither exhibits a confirmed bullish trend. The verdict reflects a probabilistic, catalyst-based preference rather than a definitive call on either company's ultimate clinical or commercial success.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a Buy and CMMB is a Hold.
CANF's RSI Indicator descends into oversold zone
The RSI Indicator for CANF moved into overbought territory on November 11, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 71 cases where CANF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for CANF just turned positive on November 02, 2026. Looking at past instances where CANF's MACD turned positive, the stock continued to rise in 30 of 39 cases over the following month. The odds of a continued upward trend are 77%.
Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where CANF advanced for three days, in 153 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CANF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CANF as a result. In 74 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CANF entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.715) is normal, around the industry mean (3.498). P/E Ratio (-0.349) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (8.621) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CANF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CANF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CMMB's RSI Indicator recovers from oversold territory
The RSI Indicator for CMMB moved out of oversold territory on October 28, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 37 of the 41 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on CMMB as a result. In 61 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for CMMB just turned positive on October 27, 2026. Looking at past instances where CMMB's MACD turned positive, the stock continued to rise in 35 of 39 cases over the following month. The odds of a continued upward trend are 90%.
Following a +3.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where CMMB advanced for three days, in 195 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMMB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CMMB broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CMMB entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.114) is normal, around the industry mean (3.498). P/E Ratio (-1.375) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. CMMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CANF | CMMB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 2 | 42 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 54 Fair valued | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 86 | 75 | |
P/E GROWTH RATING 1..100 | 9 | 30 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CMMB's Valuation (42) in the Biotechnology industry is in the same range as CANF (54). This means that CMMB’s stock grew similarly to CANF’s over the last 12 months.
CMMB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CANF (100). This means that CMMB’s stock grew similarly to CANF’s over the last 12 months.
CMMB's SMR Rating (98) in the Biotechnology industry is in the same range as CANF (100). This means that CMMB’s stock grew similarly to CANF’s over the last 12 months.
CMMB's Price Growth Rating (75) in the Biotechnology industry is in the same range as CANF (86). This means that CMMB’s stock grew similarly to CANF’s over the last 12 months.
CANF's P/E Growth Rating (9) in the Biotechnology industry is in the same range as CMMB (30). This means that CANF’s stock grew similarly to CMMB’s over the last 12 months.
| CANF | CMMB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 83% | 1 day ago 81% |
| MACD ODDS (%) | 1 day ago 77% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 90% |
| Advances ODDS (%) | 3 days ago 77% | 1 day ago 84% |
| Declines ODDS (%) | 1 day ago 87% | 17 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 79% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CANF’s FA Score shows that 1 FA rating(s) are green while CMMB’s FA Score has 1 green FA rating(s).
- CANF’s FA Score: 1 green, 4 red.
- CMMB’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CANF’s TA Score shows that 6 TA indicator(s) are bullish while CMMB’s TA Score has 4 bullish TA indicator(s).
- CANF’s TA Score: 6 bullish, 2 bearish.
- CMMB’s TA Score: 4 bullish, 4 bearish.
Price Growth
CANF (@Biotechnology) experienced а +2.47% price change this week, while CMMB (@Biotechnology) price change was +9.76% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
CMMB is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CANF and
Correlation & Price change
A.I.dvisor indicates that over the last year, CANF has been closely correlated with GNPX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if CANF jumps, then GNPX could also see price increases.
| Ticker / NAME | Correlation To CANF | 1D Price Change % | ||
|---|---|---|---|---|
| CANF | 100% | -6.63% | ||
| GNPX - CANF | 93% Closely correlated | +9.57% | ||
| ICU - CANF | 91% Closely correlated | +1.05% | ||
| MLEC - CANF | 89% Closely correlated | N/A | ||
| LONA - CANF | 78% Closely correlated | -3.48% | ||
| NCEL - CANF | 62% Loosely correlated | -2.10% | ||
More | ||||